Preview

Obstetrics, Gynecology and Reproduction

Advanced search

DIRECT ORAL ANTICOAGULANTS

https://doi.org/10.17749/2313-7347.2015.10.1.011-025

Full Text:

Abstract

Several direct oral anticoagulants (DOACs), namely, apixaban, rivaroxaban, and dabigatran etexilate, are currently licensed in Europe and the United States for various thromboembolic indications. They provide alternatives to low molecular weight heparin in a peri-operative setting for venous thromboembolism (VTE) prophylaxis and therapy and to vitamin K antagonists for longer term therapy. Routine coagulation monitoring is not required with DOACs but is recommended in patients with renal impairment, acute bleeding, overdoses, or emergency surgery. If bleeding is life-threatening, the offlabel therapeutic use of PCC or activated PCC may be considered in an attempt to reverse the anticoagulant effect of DOACs. DOACs provide important advantages in the short-term prophylaxis of VTE in patients undergoing hip or knee replacement surgery and in the longer term treatment of VTE and prevention of stroke in patients with atrial fibrillation compared with traditional agents, including reductions in dangerous bleeding types.

About the Authors

I. Tzoran
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel Internal Medicine C, Rambam Health Care Campus, Haifa, Israel Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
Russian Federation

MD, Deputy Director, Internal Medicine C Rambam Health Care Campus. P.O. Box 9602, Haifa 31096, Israel. Tel: +(972)47772029. Fax: +(972)47772343.



B. Brenner
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
Russian Federation

MD, Professor, Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel, Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel



References

1. Bristol-Myers Squibb, Pfizer EEIG. Eliquis (apixaban) Summary of Product Characteristics. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. (accessed: 10.10.2015).

2. Bristol-Myers Squibb Company, Pfizer Inc. Eliquis (apixaban) Prescribing Information. 2014. Available at: http://packageinserts.bms. com/pi/pi_eliquis.pdf. (accessed: 10.10.2015).

3. Bayer Pharma AG. Xarelto (rivaroxaban) Summary of Product Characteristics. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. 4 (accessed: 10.10.2015).

4. Janssen Pharmaceuticals Inc. Xarelto (rivaroxaban) Prescribing Information. 2014. Available at: http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf. (accessed: 10.10.2015).

5. Boehringer Ingelheim International GmbH. Pradaxa (dabigatran etexilate) Summary of Product Characteristics. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. (accessed: 10.10.2015)

6. Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa (dabigatran etexilate) Prescribing Information. 2014. Available at: http://bidocs. boehringer-ingelheim.com/BIWebAccess/ ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing Information/PIs/ Pradaxa/Pradaxa.pdf. (accessed: 10.10.2015)

7. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093-2104.

8. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369: 1406-1415.

9. Eikelboom JW, Weitz J.I. New anticoagulants. Circulation. 2010; 121: 1523-1532.

10. Levy J.H., Faraoni D., Spring J.L., Douketis J.D., Samama C.M. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology. 2013; 118: 1466-1474.

11. Samama M.M., Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011; 49: 761-772.

12. Schulman S., Bijsterveld N.R. Anticoagulants and their reversal. Transfus Med Rev. 2007; 21: 37-48.

13. Kearon C., Akl E.A., Comerota A.J., et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141: e419S-e494S.

14. Bristol-Myers Squibb Canada Inc., Pfizer Canada Inc. Eliquis (apixaban) Product Monograph. 2014. Available at: http://www.bmscanada.ca/static/products/en/pm_pdf/ELIQUIS_EN_PM.pdf. (accessed: 10.10.2015)

15. Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Portman R.J. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009; 361: 594-604.

16. Lassen M.R., Raskob G.E., Gallus A., et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010; 375: 807-815.

17. Lassen M.R., Gallus A., Raskob G.E., et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010; 363: 2487-2498.

18. Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369: 799-808.

19. Agnelli G., Buller H.R., Cohen A., et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368: 699-708.

20. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364: 806-817.

21. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992.

22. Alexander J.H., Lopes R.D., James S., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011; 365: 699-708.

23. Eriksson B.I., Borris L.C., Friedman R.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358: 2765-2775.

24. Kakkar A.K., Brenner B., Dahl O.E., et al. Extended duration rivaroxaban versus shortterm enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372: 31-39.

25. Lassen M.R., Ageno W., Borris L.C., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358: 2776-2786.

26. Turpie A.G.G., Lassen M.R., Davidson B.L., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 373: 1673-1680.

27. Eriksson B.I., Kakkar A.K., Turpie A.G.G., et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br. 2009; 91: 636-644.

28. Turpie A.G.G., Lassen M.R., Eriksson B.I., et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost. 2011; 105: 444-453.

29. Lassen M.R., Gent M., Kakkar A.K., et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. J Bone Joint Surg Br. 2012; 94: 1573-1578.

30. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363: 2499-2510.

31. The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366: 1287-1297.

32. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-891.

33. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9-19.

34. Eriksson B.I., Dahl O.E., Rosencher N., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, doubleblind, non-inferiority trial. Lancet. 2007; 370: 949-956.

35. Eriksson B.I., Dahl O.E., Huo M.H., et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011; 105: 721-729.

36. Eriksson B.I., Dahl O.E., Rosencher N., et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5: 2178-2185.

37. The RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009; 24: 1-9.

38. Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361: 2342-2352.

39. Schulman S., Kakkar A.K., Goldhaber S.Z., et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; 129: 764-772.

40. Schulman S., Kearon C., Kakkar A.K., et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013; 368: 709-718.

41. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.

42. Connolly S.J., Wallentin L., Ezekowitz M.D., et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation. 2013; 128: 237-243.

43. Schulman S., Beyth R.J., Kearon C., Levine M.N. American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008; 133: 257-298.

44. Dale B., Eikelboom J.W., Weitz J.I., et al. Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis. 2013; 35: 295-301.

45. Eriksson B.I., Quinlan D.J., Eikelboom J.W. Novel oral Factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011; 62: 41-57.

46. Bristol-Myers Squibb. Coumadin (warfarin sodium) Prescribing Information. 2011. Available at: http://packageinserts.bms.com/pi/pi_coumadin.pdf. (accessed: 10.10.2015)

47. Troconiz I.F., Tillmann C., Liesenfeld K.H., Schafer H.G., Stangier J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol. 2007; 47: 371-382.

48. Weinz C., Schwarz T., Kubitza D., Mueck W., Lang D. Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos. 2009; 37: 1056-1064.

49. Mueck W., Kubitza D., Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013; 76: 455-466.

50. Zhang D., He K., Raghavan N., et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos. 2009; 37: 1738-1748.

51. Stangier J., Rathgen K., Stahle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010; 49: 259-268.

52. Heidbuchel H., Verhamme P., Alings M., et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013; 15: 625-651.

53. Stangier J., Stahle H., Rathgen K., Roth W., Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008; 48: 1411-1419.

54. Kubitza D., Roth A., Becka M., et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban – an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013; 76: 89-98.

55. Graff J., Harder S. Anticoagulant therapy with the oral direct Factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet. 2013; 52: 243-254.

56. Kubitza D., Becka M., Zuehlsdorf M., Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006; 46: 549-558.

57. Stampfuss J., Kubitza D., Becka M., Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther. 2013; 51: 549-561.

58. Mendell J., Tachibana M., Shi M., Kunitada S. Effects of food on the pharmacokinetics of edoxaban, an oral direct Factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol. 2011; 51: 687-694.

59. Turpie A.G.G., Kreutz R., Llau J., Norrving B., Haas S. Management consensus guidance for the use of rivaroxaban - an oral, direct Factor Xa inhibitor. Thromb Haemost. 2012; 108: 876-886.

60. Lindhoff-Last E., Ansell J., Spiro T., Samama M.M. Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays. Ann Med. 2013; 45: 423-429.

61. Barrett Y.C., Wang Z., Frost C., Shenker A. Clinical laboratory measurement of direct Factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010; 104: 1263-1271.

62. van Ryn J., Baruch L., Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med. 2012; 125: 417-420.

63. Stangier J., Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012; 23: 138-143.

64. Stangier J., Rathgen K., Stahle H., Gansser D., Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64: 292-303.

65. Spyropoulos A.C., Douketis J.D. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012; 120: 2954-2962.

66. Gogarten W., Vandermeulen E., Van Aken H., Kozek S., Llau J.V., Samama C.M.; Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010; 27: 999-1015.

67. Sié P., Samama C.M., Godier A., et al. Surgery and invasive procedures in patients on longterm treatment with direct oral anticoagulants: thrombin or Factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis. 2011; 104: 669-676.

68. Heidbuchel H., Verhamme P., Alings M., et al. EHRA practical guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation: executive summary. Eur Heart J. 2013; 34: 2094-2106.

69. Healey J.S., Eikelboom J., Douketis J., et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation. 2012; 126: 343-348.

70. Sherwood M.W., Douketis J.D., Patel M.R., et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from ROCKET AF. Circulation. 2014; 129: 1850-1859.

71. Weinz C., Buetehorn U., Daehler H.P., et al. Pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – in rats and dogs. Xenobiotica. 2005; 35: 891-910.

72. Khadzhynov D., Wagner F., Formella S., et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost. 2013; 109: 596-605.

73. Pragst I., Zeitler S.H., Doerr B., et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost. 2012; 10: 1841-1848.

74. Godier A., Miclot A., Le Bonniec B., et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology. 2012; 116: 94-102.

75. Lambourne M.D., Eltringham-Smith L.J., Gataiance S., Arnold D.M., Crowther M.A., Sheffield W.P. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost. 2012; 10: 1830-1840.

76. Perzborn E., Gruber A., Tinel H., et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost. 2013; 110: 162-172.

77. Martin A.C., Le Bonniec B., Fischer A.M., et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol. 2013; 168: 4228-4233.

78. Zhou W., Zorn M., Nawroth P., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke. 2013; 44: 771-778.

79. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., Meijers J.C., Buller H.R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124: 1573-1579.

80. Marlu R., Hodaj E., Paris A., Albaladejo P., Crackowski J.L., Pernod G. Effect of nonspecific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012; 108: 217-224.

81. Fukuda T., Honda Y., Kamisato C., Morishima Y., Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost. 2012; 107: 253-259.

82. Körber M.K., Langer E., Ziemer S., Perzborn E., Gericke C., von Heymann C. Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study. Clin Appl Thromb Hemost. 2014; 20: 735-740.

83. Khoo T.L., Weatherburn C., Kershaw G., Reddel C.J., Curnow J., Dunkley S. The use of FEIBA(R) in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol. 2013; 35: 222-224.

84. Levi M., Moore K., Castillejos C., et al. Comparison of three- and four-factor prothrombin complex concentrates on the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost. 2014; 12: 1428-1436.

85. Pernod G., Albaladejo P., Godier A., et al. Management of major bleeding complications and emergency surgery in patients on longterm treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013.Arch Cardiovasc Dis. 2013; 106: 382-393.

86. Lu G., DeGuzman F.R., Hollenbach S.J., et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013; 19: 446-451.

87. Pollack C.V. Jr., Reilly P.A., Eikelboom J., Glund S., Verhamme P., Bernstein R.A., Dubiel R., Huisman M.V., Hylek E.M., Kamphuisen P.W., Kreuzer J., Levy J.H., Sellke F.W., Stangier J., Steiner T., Wang B., Kam C.W., Weitz J.I. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015; 373: 511-520.


For citation:


Tzoran I., Brenner B. DIRECT ORAL ANTICOAGULANTS. Obstetrics, Gynecology and Reproduction. 2016;10(1):11-25. (In Russ.) https://doi.org/10.17749/2313-7347.2015.10.1.011-025

Views: 283


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)